The University of Chicago Header Logo

Connection

Michael H. Davidson to United States

Back to Details
This is a "connection" page, showing publications Michael H. Davidson has written about United States.
Michael H. Davidson
Connection Strength
0.768
United States
  1. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. Endocr Pract. 2017 Apr; 23(Suppl 2):1-87.
    View in: PubMed
    Score: 0.062
  2. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. Endocr Pract. 2013 May-Jun; 19(3):536-57.
    View in: PubMed
    Score: 0.047
  3. Bl-1020, a new ?-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study. J Clin Psychiatry. 2012 Sep; 73(9):e1168-74.
    View in: PubMed
    Score: 0.045
  4. Focusing on high-density lipoprotein for coronary heart disease risk reduction. Cardiol Clin. 2011 Feb; 29(1):105-22.
    View in: PubMed
    Score: 0.041
  5. Medical and cost burden of atherosclerosis among patients treated in routine clinical practice. J Med Econ. 2010; 13(3):500-7.
    View in: PubMed
    Score: 0.038
  6. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. Clin Ther. 2009 Dec; 31(12):2824-38.
    View in: PubMed
    Score: 0.037
  7. Hypercholesterolemia treatment patterns and low-density lipoprotein cholesterol monitoring in patients with a diagnosis of atherosclerosis in clinical practice. Am J Med. 2009 Jan; 122(1 Suppl):S51-9.
    View in: PubMed
    Score: 0.035
  8. Introduction. U.S. incidence of coronary artery disease. Am J Cardiol. 2008 Jun 16; 101(12A):1F-2F.
    View in: PubMed
    Score: 0.034
  9. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther. 2008 Mar; 6(3):391-409.
    View in: PubMed
    Score: 0.033
  10. Differences between clinical trial efficacy and real-world effectiveness. Am J Manag Care. 2006 Nov; 12(15 Suppl):S405-11.
    View in: PubMed
    Score: 0.030
  11. Statin safety: an appraisal from the adverse event reporting system. Am J Cardiol. 2006 Apr 17; 97(8A):32C-43C.
    View in: PubMed
    Score: 0.029
  12. Statin safety: an assessment using an administrative claims database. Am J Cardiol. 2006 Apr 17; 97(8A):61C-68C.
    View in: PubMed
    Score: 0.029
  13. Application of recent definitions of the metabolic syndrome to survey data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE II). J Cardiometab Syndr. 2006; 1(5):295-300.
    View in: PubMed
    Score: 0.029
  14. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2005 Jan 01; 95(1):120-2.
    View in: PubMed
    Score: 0.027
  15. Lipid management and the elderly. Prev Cardiol. 2003; 6(3):128-33; quiz 134-5.
    View in: PubMed
    Score: 0.023
  16. A symposium: National Cholesterol Education Program Adult Treatment Panel III: Impact and implementation of the new guidelines. Introduction. Am J Cardiol. 2002 Mar 07; 89(5A):1C-2C.
    View in: PubMed
    Score: 0.022
  17. Strategies to improve Adult Treatment Panel III guideline adherence and patient compliance. Am J Cardiol. 2002 Mar 07; 89(5A):8C-20C; discussion 20C-22C.
    View in: PubMed
    Score: 0.022
  18. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol. 2002 Feb 01; 89(3):268-75.
    View in: PubMed
    Score: 0.022
  19. Long-term safety of risperidone. J Clin Psychiatry. 2001; 62 Suppl 21:26-8.
    View in: PubMed
    Score: 0.020
  20. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary. Endocr Pract. 2020 Oct; 26(10):1196-1224.
    View in: PubMed
    Score: 0.020
  21. What kinds of data should be available to probe the effects of nutrients, food supplements or vitamins on serum lipoprotein levels and/or atherosclerosis? Am J Cardiol. 1998 Apr 23; 81(8A):80F-83F.
    View in: PubMed
    Score: 0.017
  22. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE - EXECUTIVE SUMMARYComplete Appendix to Guidelines available at http://journals.aace.com. Endocr Pract. 2017 Apr 02; 23(4):479-497.
    View in: PubMed
    Score: 0.015
  23. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2015 EXECUTIVE SUMMARY. Endocr Pract. 2015 Dec; 21(12):1403-14.
    View in: PubMed
    Score: 0.014
  24. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis. 2009 May; 204(1):208-15.
    View in: PubMed
    Score: 0.009
  25. The editor's roundtable: lipid management beyond statins-reducing residual cardiovascular risk. Am J Cardiol. 2008 Sep 01; 102(5):559-67.
    View in: PubMed
    Score: 0.009
  26. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008 Apr 15; 51(15):1512-24.
    View in: PubMed
    Score: 0.008
  27. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008 Apr; 31(4):811-22.
    View in: PubMed
    Score: 0.008
  28. Type 2 diabetes and cardiovascular disease: reducing the risk. J Manag Care Pharm. 2007 Mar; 13(2 Suppl A):S2-15; quiz S16-7.
    View in: PubMed
    Score: 0.008
  29. A comparison of Canadian and American guidelines for lipid management using data from the National Cholesterol Education Program Evaluation ProjecT Utilizing Novel E-technology (NEPTUNE) II survey. Can J Cardiol. 2006 Mar 15; 22(4):315-22.
    View in: PubMed
    Score: 0.007
  30. Contemporary awareness and understanding of cholesterol as a risk factor: results of an American Heart Association national survey. Arch Intern Med. 2003 Jul 14; 163(13):1597-600.
    View in: PubMed
    Score: 0.006
  31. Comparison of the efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia. Am J Cardiol. 2001 Sep 15; 88(6):635-9.
    View in: PubMed
    Score: 0.005
  32. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr Med Res Opin. 2001; 17(1):43-50.
    View in: PubMed
    Score: 0.005
  33. Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group. Am J Cardiol. 1998 Aug 01; 82(3):311-6.
    View in: PubMed
    Score: 0.004
  34. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin. Pharmacoeconomics. 1998 Jul; 14(1):59-70.
    View in: PubMed
    Score: 0.004
  35. Panel discussion: what is the future of macronutrient substitutes in North America? Regul Toxicol Pharmacol. 1996 Feb; 23(1 Pt 2):S51-9.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.